Open Collections

UBC Faculty Research and Publications

Inhaled long acting β2 agonists for COPD University of British Columbia. Therapeutics Initiative

Description

Therapeutics Letter 109 considers Inhaled long acting β2 agonists for COPD. Conclusions: The doses most studied in COPD clinical trials are formoterol 9 and 12 μg twice daily and salmeterol 50 μg twice daily. The four inhaled long acting β2 agonists (indacaterol, formoterol, arformoterol and salmeterol) do not prolong survival or reduce the risk of hospitalization (total serious adverse events) in patients with COPD. Evidence for improvement of symptom scores is of low quality and insufficient to justify long-term use. A subset of patients may derive clinically important symptomatic relief. Such patients can be identified on a case-by-case basis using a short therapeutic trial.

Item Metadata

Title
Inhaled long acting β2 agonists for COPD
Alternate Title
Therapeutics Letter 109
Creator
University of British Columbia. Therapeutics Initiative
Date Issued
2017-12
Description
Therapeutics Letter 109 considers Inhaled long acting β2 agonists for COPD. Conclusions: The doses most studied in COPD clinical trials are formoterol 9 and 12 μg twice daily and salmeterol 50 μg twice daily. The four inhaled long acting β2 agonists (indacaterol, formoterol, arformoterol and salmeterol) do not prolong survival or reduce the risk of hospitalization (total serious adverse events) in patients with COPD. Evidence for improvement of symptom scores is of low quality and insufficient to justify long-term use. A subset of patients may derive clinically important symptomatic relief. Such patients can be identified on a case-by-case basis using a short therapeutic trial.
Subject
Adverse Events; Formoterol Fumarate; Indacaterol; Morbidity; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433688
URI
http://hdl.handle.net/2429/85098
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International